secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052121
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion Q1 2024 net loss $39.1M; cash $145.3M; positive diabetes clinical data
--------------------------------------------------------------------------------

- Net loss of $39.1M in Q1 2024 (incl. $5.0M stock comp) vs $29.1M in Q1 2023; R&D expenses rose to $33.8M.
- Cash, equivalents and restricted cash $145.3M at March 31, 2024, down from $177.2M at Dec 31, 2023.
- In type 2 diabetes COVALENT-111, 20%/36% of 100mg/200mg cohorts achieved durable HbA1c ≥1.0% reduction off therapy at 26 weeks.
- In type 1 diabetes COVALENT-112, first two patients showed improved beta-cell function (C-peptide Index) after BMF-219; well tolerated.
- Plan to report Week 26 data from >200 T2D patients (~40 T1D patients) in 2024; expect lower opex in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/0000950170-24-052121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/bmea-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer